Clinical Characteristics and Prognostic Factors of Patients With COVID-19

Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

Study Overview

• Status: Unknown
• Conditions: Coronavirus
• Intervention / Treatment: Other: retrospective analysis

Detailed Description

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

• Study Type: Observational
• Enrollment (Anticipated): 120

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, +86200072
      • Recruiting
      • Shanghai 10th People's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with COVID-19

Description

Inclusion Criteria:

• Adult aged >=18years old; Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.

Exclusion Criteria:

• Near-death state (expected survival time less than 24 hours); Malignant tumor; Pregnancy or puerperium women; Patients who refused to participant.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
COVID-19 patients; Hospitalized patients with COVID-19	Other: retrospective analysis; The investigators retrospectively analyzed the hospitalized patients with COVID-19

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to negative conversion of severe acute respiratory syndrome coronavirus 2	The primary outcome is the time to negative conversion of coronavirus	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of stay in hospital	The time of hospitalization	1 month
Survival	The rate of survival within hospitalization of these patients will be tracked. The rate of survival within hospitalization of these patients will be tracked. The rate of survival within hospitalization of these patients will be tracked. The rate of survival within hospitalization of these patients will be tracked.	1 month
Intubation	The rate of intubation within hospitalization of these patients will be tracked	1 month

Collaborators and Investigators

• Sponsor: Shanghai 10th People's Hospital
• Collaborators: Chibi People's Hospital, Hubei Province

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 30, 2020
• Primary Completion (ANTICIPATED): April 2, 2020
• Study Completion (ANTICIPATED): April 15, 2020

Study Registration Dates

• First Submitted: March 27, 2020
• First Submitted That Met QC Criteria: March 30, 2020
• First Posted (ACTUAL): March 31, 2020

Study Record Updates

• Last Update Posted (ACTUAL): March 31, 2020
• Last Update Submitted That Met QC Criteria: March 30, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Coronavirus Infections
• Other Study ID Numbers: HBCBH-IEC-2020-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No